Related Experiment Video
Updated: Jan 24, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity
Nobunori Takahashi1, Toshihisa Kojima2, Daihei Kida3
1Department of Orthopedic Surgery and Rheumatology, Nagoya University Hospital, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8550, Japan. nobunori@med.nagoya-u.ac.jp.
Objective:
To compare the clinical outcomes of abatacept between rheumatoid arthritis patients with and without concomitant methotrexate (MTX) treatment in daily clinical practice.
Methods:
A retrospective cohort study was performed using data from a multicentre registry. A total of 176 consecutive rheumatoid arthritis patients treated with abatacept were included. The propensity score based on multiple baseline characteristic variables was calculated, and 41 of 86 patients treated without MTX (MTX(-)) and 41 of 90 patients treated with concomitant MTX (MTX(+)) were statistically extracted and analysed. Clinical outcomes were evaluated and compared between the two groups over a 52-week period.
Results:
Baseline characteristics were statistically comparable. No significant differences were observed in the following clinical outcomes from baseline throughout the 52-week period: drug retention rate (MTX(-)/MTX(+) 79.1%/80.5%), mean change in disease activity score based on 28 joints (DAS28-CRP) from baseline (- 1.35/- 1.54), low disease activity rate (48.8%/43.9%), clinical remission rate (31.7%/36.6%), moderate European League Against Rheumatism (EULAR) response rate (68.3%/68.3%), and good EULAR response rate (36.6%/41.1%) at 52 weeks.
Conclusion:
In rheumatoid arthritis patients with similar background characteristics undergoing abatacept treatment, concomitant MTX does not seem to affect clinical outcomes. Abatacept would be a suitable treatment option in daily clinical practice in patients with contraindications to MTX.
Key Points:
• This is the first study to directly compare the clinical efficacy and safety of abatacept between patients with and without concomitant methotrexate (MTX) treatment in 'real-world' settings using the propensity score matching method. • There were no significant differences in clinical outcomes of abatacept between patients with and without concomitant MTX treatment. • We used data from a large Japanese multicentre registry for biologics in rheumatoid arthritis, thereby decreasing selection bias based on the personal preferences of physicians.
Insights
In rheumatoid arthritis, abatacept showed similar clinical outcomes whether or not patients also took methotrexate (MTX). This suggests abatacept is a viable treatment option, even for those who cannot take MTX.
Area of Science:
- Rheumatology
- Immunology
- Clinical Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease.
- Abatacept is a biologic therapy used for RA treatment.
- The role of concomitant methotrexate (MTX) with abatacept in RA management requires further clarification in real-world settings.
Purpose of the Study:
- To compare the clinical outcomes of abatacept in rheumatoid arthritis patients with and without concomitant methotrexate (MTX) treatment.
- To evaluate the efficacy and safety of abatacept in routine clinical practice.
Main Methods:
- Retrospective cohort study utilizing a multicentre registry.
- Propensity score matching was employed to create comparable groups of patients with (MTX(+)) and without (MTX(-)) concomitant MTX.
- Clinical outcomes were assessed over a 52-week period.
Main Results:
- Baseline characteristics were comparable between the MTX(-) and MTX(+) groups.
- No significant differences were observed in drug retention rates, disease activity scores (DAS28-CRP), low disease activity rates, clinical remission rates, or EULAR response rates at 52 weeks.
- Specific outcomes included drug retention (79.1%/80.5%), mean DAS28-CRP change (-1.35/-1.54), and good EULAR response (36.6%/41.1%) at 52 weeks.
Conclusions:
- Concomitant methotrexate does not appear to significantly affect the clinical outcomes of abatacept treatment in RA patients with similar baseline characteristics.
- Abatacept is a suitable treatment option in daily practice, particularly for RA patients with contraindications to MTX.
- This study provides real-world evidence on abatacept efficacy, minimizing physician bias through registry data analysis.
More Related Videos
07:44Author Spotlight: Implementation of BIVA for Analyzing Disease Risk Factors in Patients with Low Body Cell Mass
Published on: July 14, 2023
06:55Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Related Concept Videos
Sign Test for Matched Pairs
To conduct the sign test, we first calculate the differences in...
Introduction to z Scores
z scores...
Introduction to z Scores
z scores...
z Scores and Area Under the Curve
Predicting Reaction Outcomes
Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...